Literature DB >> 789085

Clinical pharmacokinetics of pancuronium bromide.

A A Somogyi, C A Shanks, E J Triggs.   

Abstract

Plasma concentrations of pancuronium bromide have been studied in seven surgical patients following a 6 mg intravenous bolus injection of the drug for neuromuscular blockade. Concurrently, evoked muscle twitch response was monitored for each patient as a measure of the pharmacodynamic effect of the drug. The plasma decay curve for pancuronium was found to be biphasic and after rigorous statistical analysis the data were interpreted according to a 2-compartment open model. The half-life of the beta-phase varied between 89.5 and 161.5 min. The apparent volume of distribution of the central compartment ranged from 62.9 to145.5 ml/kg and the plasma clearance from 57.6 to 187.3 ml/min. At the first sign of recovery from neuro-muscular blockade the mean pancuronium plasma level was found to be 0.218 mcg/ml. The mean duration of action as measured from time of onset of paralysis to 20% recovery was 83.4 min with the plasma level at 20% being 0.169 mcg/ml corresponding to 45.4% of dose remaining to be eliminated from the body.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 789085     DOI: 10.1007/bf00565627

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  COMPARISON OF ELECTRICAL AND MECHANICAL RECORDING OF SPONTANEOUS AND EVOKED MUSCLE ACTIVITY. THE CLINICAL VALUE OF CONTINUOUS RECORDING AS AN AID TO THE RATIONAL USE OF MUSCLE RELAXANTS DURING ANESTHESIA.

Authors:  R L KATZ
Journal:  Anesthesiology       Date:  1965 Mar-Apr       Impact factor: 7.892

2.  [The metabolism of pancuronium in man].

Authors:  W Buzello
Journal:  Anaesthesist       Date:  1975-01       Impact factor: 1.041

3.  The effect of renal failure and hyperkalemia on the duration of pancuronium neuromuscular blockade in man.

Authors:  R D Miller; W C Stevens; W L Way
Journal:  Anesth Analg       Date:  1973 Jul-Aug       Impact factor: 5.108

4.  The use of pancuronium bromide in operations for renal insufficiency. Case reports.

Authors:  S Kamvyssi-Dea; K Papadimitriou; P Dousaitou
Journal:  Br J Anaesth       Date:  1972-11       Impact factor: 9.166

5.  Fluorimetric and chromatographic determination of pancuronium bromide and its metabolites in biological materials.

Authors:  U W Kersten; D K Meijer; S Agoston
Journal:  Clin Chim Acta       Date:  1973-02-28       Impact factor: 3.786

6.  The fate of pancuronium bromide in man.

Authors:  S Agoston; G A Vermeer; U W Kertsten; D K Meijer
Journal:  Acta Anaesthesiol Scand       Date:  1973       Impact factor: 2.105

7.  Kinetics of the elimination and neuromuscular blocking effect of d-tubocurarine in man.

Authors:  M Gibaldi; G Levy; W Hayton
Journal:  Anesthesiology       Date:  1972-03       Impact factor: 7.892

8.  Commentary. Drug distribution and pharmacologic effects.

Authors:  M Gibaldi; G Levy; H Weintraub
Journal:  Clin Pharmacol Ther       Date:  1971 Sep-Oct       Impact factor: 6.875

9.  Pharmacokinetics--uses and abuses.

Authors:  P J Fell; M T Stevens
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

10.  Proceedings: Plasma concentrations of pancuronium bromide (pavulon) in patients with normal and impaired renal function.

Authors:  K McLeod; M J Watson; M D Rawlins
Journal:  Br J Anaesth       Date:  1975-08       Impact factor: 9.166

View more
  9 in total

1.  Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?

Authors:  T M Beaufort; J H Proost; K Kuizenga; M C Houwertjes; U W Kleef; J M Wierda
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

Review 2.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 3.  Anaesthesia in the elderly. Special considerations.

Authors:  A G Jones; J M Hunter
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

Review 4.  Pharmacokinetics in intravenous anaesthetic practice.

Authors:  P Duvaldestin
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of the non-depolarising muscle relaxants.

Authors:  M I Ramzan; A A Somogyi; J S Walker; C A Shanks; E J Triggs
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

6.  The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide.

Authors:  A A Somogyi; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

7.  Clinical pharmacokinetics of alcuronium chloride in man.

Authors:  J Walker; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

8.  Pancuronium blood level monitoring in patients with tetanus.

Authors:  P Duvaldestin; C Gibert; D Henzel; P Guy; J M Desmonts
Journal:  Intensive Care Med       Date:  1979-09       Impact factor: 17.440

9.  An analytical pharmacodynamic model for nondepolarizing neuromuscular blocking agents.

Authors:  A d'Hollander; C Delcroix
Journal:  J Pharmacokinet Biopharm       Date:  1981-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.